Peer-Reviewed Study: Sanara MedTech's CellerateRX® Cuts Spine Surgery Costs by $3,852 Per Patient
SMTI is trading near its 52-week low of $18.29 (7.7% above the low).
Summary
Sanara MedTech Inc. announced the publication of a peer-reviewed study in the Journal of Medical Economics, demonstrating significant economic and clinical value for its CellerateRX® Surgical Powder. The study found that CellerateRX generated $3,852 in cost savings and a 0.007 quality-adjusted life year (QALY) gain per patient for high-risk spinal surgery patients, primarily by avoiding hospital readmissions and surgical revisions. This independent, peer-reviewed validation is a critical catalyst for a medical technology company of SMTI's size, as it provides strong evidence to drive product adoption among healthcare providers and support favorable reimbursement discussions. Traders will closely watch how the company leverages these compelling findings to accelerate sales growth and expand market penetration for CellerateRX.
At the time of this announcement, SMTI was trading at $19.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $175.9M. The 52-week trading range was $18.29 to $35.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.